Merck Secures Experimental B-Cell Therapy in $13 Billion Deal

Acquisition Strengthens Drugmaker's Pipeline

Key Points:

• Merck has agreed to purchase an experimental drug targeting B-cell associated diseases.
• The deal is valued at up to $13 billion, including $700 million in upfront cash.
• The transaction represents Merck's latest move to expand its presence in the biotechnology sector.

In a significant move, Merck Co. has announced an agreement to acquire an investigational drug targeting B-cell associated diseases. The deal, worth up to $13 billion, underscores Merck's ongoing commitment to innovation and strengthens its drug development pipeline.

Under the terms of the agreement, Merck will pay an upfront cash payment of $700 million. The remaining $12.3 billion will be contingent upon the achievement of certain milestones related to the drug's development and commercialization.

The acquisition of this experimental therapy aligns closely with Merck's strategic priorities. By expanding its presence in the B-cell depletion therapy space, Merck seeks to address unmet medical needs in a range of diseases.